Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine.

Abstract

INTRODUCTION:

As limited data among German women exist about HPV, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae, we report the prevalence of these genital infections and general baseline demographics of the young German women enrolled in the phase III trials of the quadrivalent HPV vaccine.

MATERIALS AND METHODS:

German females (n = 437; 9-23 years) were recruited among 3 international phase 3 studies of an HPV-6/11/16/18 vaccine. We present baseline characteristics, prevalence of HPV-6/11/16/18 and, for women aged 16-23, abnormal cervical cytology and sexually transmitted diseases.

RESULTS:

Chlamydia trachomatis and Neisseria gonorrhoeae prevalence was 5 and 0.3%, respectively. Approximately 17% of participants had HPV-6, 11, 16, or 18 DNA or antibodies. All subjects <17 years were naïve to the four vaccine types.

DISCUSSION:

The results of the vaccine trials have demonstrated that it is worth administering prophylactic HPV vaccines before sexual debut; however, none of these sexually active German women were positive to all four types and most were positive to only one type. Thus, all women had the potential to benefit from vaccination with a quadrivalent HPV vaccine.

• Authors: Elisabeth Barthell, Linn Woelber, Karin Hellner, Birka Camerer, Friederike Gieseking, Maik Hauschild, Ioannis Mylonas, Klaus Friese, Heather L Sings, Radha Railkar, Christine Gause, Eliav Barr
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 279 Issue 6 Pg. 803-7 (Jun 2009) ISSN: 1432-0711 [Electronic] Germany
• PMID: 18936950 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
• Papillomavirus Vaccines

Topics

• Adolescent
• Alphapapillomavirus (isolation & purification)
• Chlamydia Infections (epidemiology)
• Clinical Trials, Phase III as Topic
• Female
• Germany (epidemiology)
• Gonorrhea (epidemiology)
• Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
• Humans
• Papillomavirus Infections (epidemiology)
• Papillomavirus Vaccines
• Prevalence
• Randomized Controlled Trials as Topic
• Young Adult